For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Grant revenue | 0 | 8,726 | 322,569 | 1,757,724 |
| Research and development | 5,135,419 | 5,830,207 | 6,040,442 | 5,108,625 |
| General and administrative | 2,975,105 | 2,510,038 | 2,326,326 | 3,265,374 |
| Total operating expenses | 8,110,524 | 8,340,245 | 8,366,768 | 8,373,999 |
| Loss from operations | -8,110,524 | -8,331,519 | -8,044,199 | -6,616,275 |
| Other expense | -1,021 | 3,291 | -1,227 | -10,256 |
| Interest income | 147,387 | 240,938 | 318,787 | 368,127 |
| Total other income, net | 146,366 | 244,229 | 317,560 | 357,871 |
| Net loss | -7,964,158 | -8,087,290 | -7,726,639 | -6,258,404 |
| Net unrealized loss on marketable securities | -6,024 | -8 | 6,607 | -22,006 |
| Total comprehensive loss | -7,970,182 | -8,087,298 | -7,720,032 | -6,280,410 |
| Basic EPS | -0.86 | -0.873 | -0.84 | -0.7 |
| Basic Average Shares | 9,258,319 | 9,261,081 | 9,252,719 | 8,950,521 |
CervoMed Inc. (CRVO)
CervoMed Inc. (CRVO)